Morrison Briggs
SEC insider (Form 3/4/5 filer). CIK 0001654430. Director at ARVINAS, INC. (ARVN) and 2 other issuers. 7 reported Form 4/5 transactions since Sep 2024; latest on Jun 24, 2026. Located in BOSTON, MA.
Companies Morrison Briggs has filed insider reports for
- ARVINAS, INC. (ARVN): Director
- CRISPR Therapeutics AG (CRSP): Director
- Werewolf Therapeutics, Inc. (HOWL): Director
Morrison Briggs
CIK: 0001654430
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Jun 24, 2026ARVN
ARVINAS, INC.
AwardDirect15.5K shares- - Jun 5, 2026CRSP
CRISPR Therapeutics AG
AwardDirectStock Option (Right to Buy)
13K shares- - Mar 6, 2026ARVN
ARVINAS, INC.
PurchaseDirect20K shares at avg. $13.40$268K - Sep 22, 2025ARVN
ARVINAS, INC.
PurchaseDirect30K shares at avg. $7.57$227K - Jun 25, 2025ARVN
ARVINAS, INC.
AwardDirect16K shares- - Jun 12, 2025HOWL
Werewolf Therapeutics, Inc.
AwardDirectStock Option (right to buy)
27K shares- - Jun 5, 2025CRSP
CRISPR Therapeutics AG
AwardDirectStock Option (Right to Buy)
13K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 24, 2026 |  ARVN ARVINAS, INC. | Award | 15,527 | - | $0 | Direct |
| Jun 5, 2026 |  CRSP CRISPR Therapeutics AG | Award Stock Option (Right to Buy) | 13,000 | - | - | Direct |
| Mar 6, 2026 | ARVN ARVINAS, INC. | Purchase | 20,000 | $13.40 | $268,070 | Direct |
| Sep 22, 2025 | ARVN ARVINAS, INC. | Purchase | 30,000 | $7.57 | $227,010 | Direct |
| Jun 25, 2025 | ARVN ARVINAS, INC. | Award | 16,025 | - | - | Direct |
| Jun 12, 2025 |  HOWL Werewolf Therapeutics, Inc. | Award Stock Option (right to buy) | 27,000 | - | - | Direct |
| Jun 5, 2025 | CRSP CRISPR Therapeutics AG | Award Stock Option (Right to Buy) | 13,000 | - | - | Direct |
1-7 of 7 transactions